Immunologic alterations and the pathogenesis of organ failure in the ICU

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 5, 2011, Pages 569-580

  Opal, Steven M ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

co inhibitory signals; co stimulatory signals; Lipopolysaccharide; sepsis; sepsis induced immunosuppression; septic shock

Indexed keywords

DAMAGE ASSOCIATED MOLECULAR PATTERN MOLECULE; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; BLOOD CLOTTING; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CRITICAL ILLNESS; CYTOTOXIC LYMPHOCYTE; HELPER CELL; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; INTENSIVE CARE UNIT; LYMPHOCYTE SUBPOPULATION; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SEPSIS; TH17 CELL;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; CRITICAL ILLNESS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTENSIVE CARE UNITS; MULTIPLE ORGAN FAILURE; PATIENT SELECTION;

EID: 80054075823     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1287865     Document Type: Review

References (70)

1. Takeda K. Evolution and integration of innate immune recognition systems: the Toll-like receptors. J Endotoxin Res 2005 11 1 51-55 (Pubitemid 40533080)
2. van der Poll T, Opal S M. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008 8 1 32-43
3. Cinel I, Opal S M. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009 37 1 291-304
4. Davidson G H., Hamlat C A., Rivara F P., Koepsell T D., Jurkovich G J., Arbabi S. Long-term survival of adult trauma patients. JAMA 2011 305 10 1001-1007
5. Netea M G., van der Meer J WM. Immunodeficiency and genetic defects of pattern-recognition receptors. N Engl J Med 2011 364 1 60-70
6. Rathinam V AK, Jiang Z, Waggoner S N. et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010 11 5 395-402
7. Goodridge H S., Marshall F A., Else K J. et al. Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62. J Immunol 2005 174 1 284-293 (Pubitemid 40007415)
8. Coban C, Ishii K J., Kawai T et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 2005 201 1 19-25 (Pubitemid 40130079)
9. Angus D C., Linde-Zwirble W T., Lidicker J, Clermont G, Carcillo J, Pinsky M R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 29 7 1303-1310 (Pubitemid 32641789)
10. Dellinger R P., Levy M M., Carlet J M. et al, International Surviving Sepsis Campaign Guidelines Committee American Association of Critical-Care Nurses American College of Chest Physicians American College of Emergency Physicians Canadian Critical Care Society European Society of Clinical Microbiology and Infectious Diseases European Society of Intensive Care Medicine European Respiratory Society International Sepsis Forum Japanese Association for Acute Medicine Japanese Society of Intensive Care Medicine Society of Critical Care Medicine Society of Hospital Medicine Surgical Infection Society World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008 36 1 296-327
11. Opal S M. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int J Med Microbiol 2007 297 5 365-377 (Pubitemid 47188050)
12. Martin G S., Mannino D M., Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 348 16 1546-1554 (Pubitemid 36437931)
13. Opal S M., Calandra T. Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients? JAMA 2009 302 21 2367-2368
14. Littman D R., Rudensky A Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010 140 6 845-858
15. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004 4 7 499-511 (Pubitemid 38931765)
16. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004 430 6996 257-263 (Pubitemid 38902439)
17. Nathan C, Ding A. Nonresolving inflammation. Cell 2010 140 6 871-882
18. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 2006 58 1 117-124 (Pubitemid 44294995)
19. Levi M, Opal S M. Coagulation abnormalities in critically ill patients. Crit Care 2006 10 4 222-228
20. Riewald M, Petrovan R J., Donner A, Mueller B M., Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002 296 5574 1880-1882 (Pubitemid 34596276)
21. Coughlin S R. Thrombin signalling and protease-activated receptors. Nature 2000 407 6801 258-264
22. Tressel S L., Kaneider N C., Kasuda S et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 2011 3 7 370-384
23. Hotchkiss R S., Karl I E. The pathophysiology and treatment of sepsis. N Engl J Med 2003 348 2 138-150 (Pubitemid 36056721)
24. Hotchkiss R S., Coopersmith C M., McDunn J E., Ferguson T A. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009 15 5 496-497
25. Hotchkiss R S., Nicholson D W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006 6 11 813-822 (Pubitemid 44631650)
26. Hotchkiss R S., Opal S M. Immunotherapy for sepsisa new approach against an ancient foe. N Engl J Med 2010 363 1 87-89
27. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006 354 11 1166-1176
28. Kasten K R., Tschöp J, Adediran S G., Hildeman D A., Caldwell C C. T cells are potent early mediators of the host response to sepsis. Shock 2010 34 4 327-336
29. Patrozou E, Opal S M. What is inflammation, what is sepsis, what is MODS? In: Deutschman C S. Neligan P J. eds. Evidence-Based Practice of Critical Care. Philadelphia, PA Saunders Elsevier 2010 151-157
30. Opal S M. New perspectives on immunomodulatory therapy for bacteraemia and sepsis. Int J Antimicrob Agents 2010 36 Suppl 2 S70-S73
31. Venet F, Bohé J, Debard A-L, Bienvenu J, Lepape A, Monneret G. Both percentage of gammadelta T lymphocytes and CD3 expression are reduced during septic shock. Crit Care Med 2005 33 12 2836-2840 (Pubitemid 41816419)
32. Laudanski K, Miller-Graziano C, Xiao W et al. Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc Natl Acad Sci U S A 2006 103 42 15564-15569 (Pubitemid 44625632)
33. van de Veerdonk F L., Teirlinck A C., Kleinnijenhuis J et al. Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1. J Leukoc Biol 2010 88 2 227-232
34. Chen Z, O'Shea J J. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008 41 2 87-102
35. Chizzolini C, Chicheportiche R, Alvarez M et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008 112 9 3696-3703
36. Lavoie P M., Huang Q, Jolette E et al. Profound lack of interleukin (IL)-12/IL-23p40 in neonates born early in gestation is associated with an increased risk of sepsis. J Infect Dis 2010 202 11 1754-1763
37. Kitazawa Y, Fujino M, Wang Q et al. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007 83 6 774-782 (Pubitemid 46569197)
38. Spite M, Serhan C N. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010 107 10 1170-1184
39. Serhan C N., Chiang N, Van Dyke T E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008 8 5 349-361 (Pubitemid 351595216)
40. Serhan C N., Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005 6 12 1191-1197 (Pubitemid 43045627)
41. Schwab J M., Chiang N, Arita M, Serhan C N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007 447 7146 869-874 (Pubitemid 46920139)
42. Osuchowski M F., Welch K, Siddiqui J, Remick D G. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006 177 3 1967-1974 (Pubitemid 44092537)
43. Meisel C, Schefold J C., Pschowski R et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009 180 7 640-648
44. Trapnell B C. A novel biomarker-guided immunomodulatory approach for the therapy of sepsis. Am J Respir Crit Care Med 2009 180 7 585-586
45. Dinarello C A. Anti-inflammatory agents: present and future. Cell 2010 140 6 935-950
46. Kalil A C. A silent killer: cytomegalovirus infection in the nonimmunocompromised critically ill patient. Crit Care Med 2008 36 12 3261-3264
47. Ziemann M, Sedemund-Adib B, Reiland P, Schmucker P, Hennig H. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. Crit Care Med 2008 36 12 3145-3150
48. Hutloff A, Dittrich A M., Beier K C. et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999 397 6716 263-266
49. Wang S, Zhu G, Chapoval A I. et al. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 2000 96 8 2808-2813
50. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006 27 4 195-201
51. Keir M E., Butte M J., Freeman G J., Sharpe A H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008 26 677-704 (Pubitemid 351600389)
52. Huang X, Venet F, Wang Y L. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 2009 106 15 6303-6308
53. Brahmamdam P, Inoue S, Unsinger J, Chang K C., McDunn J E., Hotchkiss R S. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010 88 2 233-240
54. Huang X, Venet F, Wang Y L. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 2009 106 15 6303-6308
55. Albring J C., Sandau M M., Rapaport A S. et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med 2010 207 12 2551-2559
56. Watanabe N, Gavrieli M, Sedy J R. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003 4 7 670-679 (Pubitemid 36874444)
57. Vendel A C., Calemine-Fenaux J, Izrael-Tomasevic A, Chauhan V, Arnott D, Eaton D LB. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol 2009 182 3 1509-1517
58. Hurchla M A., Sedy J R., Gavrieli M, Drake C G., Murphy T L., Murphy K MB. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+T cells. J Immunol 2005 174 6 3377-3385 (Pubitemid 40354042)
59. Sedy J R., Gavrieli M, Potter K G. et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005 6 1 90-98 (Pubitemid 40136700)
60. Chemnitz J M., Lanfranco A R., Braunstein I, Riley J LB. B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J Immunol 2006 176 11 6603-6614 (Pubitemid 43787843)
61. Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp3+regulatory T cell function. Science 2008 322 5899 271-275
62. Zhu X, Marcus W D., Xu W et al. Novel human interleukin-15 agonists. J Immunol 2009 183 6 3598-3607
63. Hasegawa A, Iwasaka H, Hagiwara S, Asai N, Nishida T, Noguchi T. Alternate day calorie restriction improves systemic inflammation in a mouse model of sepsis induced by cecal ligation and puncture. J Surg Res 2010 Dec 9. [Epub ahead of print]
64. Christaki E, Opal S M., Keith J C. Jr et al. Estrogen receptor beta agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic study. J Infect Dis 2010 201 8 1250-1257
65. Cohen I, Rider P, Carmi Y et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci U S A 2010 107 6 2574-2579
66. Chen C J., Kono H, Golenbock D, Reed G, Akira S, Rock K L. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007 13 7 851-856 (Pubitemid 47038190)
67. Dinarello C A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009 27 519-550
68. Werman A, Werman-Venkert R, White R et al. The precursor form of IL-1 is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 2004 101 8 2434-2439 (Pubitemid 38269329)
69. López R A., Zorzopulos J. Vaccine shortage for pandemic influenza: can it be solved? Vaccine 2006 24 15 2701
70. Zhao G, Jin H, Li J et al. PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine. Viral Immunol 2009 22 2 131-138